KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma

(2014) Bruno V. Sinn et al.   PANCREAS

Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis

(2014) Andrea Mafficini et al.   PLoS One

KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas

(2013) Alyssa M Krasinskas et al.   MODERN PATHOLOGY

Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes

(2012) Stéphanie Moreau et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials

(2012) Marco Falasca et al.   Anti-Cancer Agents in Medicinal Chemistry

BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

(2012) Rachel N. Grisham et al.   CANCER

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

(2012) Y. Imamura et al.   CLINICAL CANCER RESEARCH

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis

(2012) Shanxiang Shen et al.   Diagnostic Pathology

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

(2012) Takeshi Ogura et al.   JOURNAL OF GASTROENTEROLOGY

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer

(2011) Melissa Oliveira-Cunha et al.   PANCREAS

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

(2011) Filip Janku et al.   PLoS One

7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction

(2010) Thomas W. Rice et al.   ANNALS OF SURGICAL ONCOLOGY

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

(2009) S. Ogino et al.   CLINICAL CANCER RESEARCH

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

(2009) Paola Ulivi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Are RAS mutations predictive markers of resistance to standard chemotherapy?

(2009) Yohann Loriot et al.   Nature Reviews Clinical Oncology

Resequencing Analysis of the Human Tyrosine Kinase Gene Family in Pancreatic Cancer

(2009) Takashi Kubo et al.   PANCREAS

Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer

(2008) A. Jimeno et al.   CANCER RESEARCH

Akt as a therapeutic target in cancer

(2008) Linda S Steelman et al.   EXPERT OPINION ON THERAPEUTIC TARGETS